21.06.2013 - Swiss vaccine developer AmVac AG has bagged EU funding in two FP7 projects worth €5.5m and €6m.
The projects aims to develop innovative vaccines against flu and leishmaniasis including Phase I safety testing. The first one of the 5-year projects is aimed at developing a universal flu vaccine that can be used over several years. While traditional flu vaccines target highly variable antigens on the virus' surface and must be adapted and newly produced each year, the new vaccine will be based on antigens that are well conserved across the strains and largely stable over time. AmVac will be involved in vaccine design and contributes its MALP adjuvant to optimize efficacy. Moreover, AmVac will support the establishment of GMP (Good Manufacturing Practice) vaccine manufacturing.
The second project targets leishmaniasis, an infectious disease transmitted by certain species of sand fly. It is found in parts of the tropics, subtropics and southern Europe. Currently, there is no vaccine available. A first-in-class vaccine could not only protect the local population but also tourists travelling to endemic regions. AmVac will support pre-clinical testing and manufacturing according to GMP standards.
Funds provided under the FP7 programme only require a 25% contribution in kind by small and medium-size companies such as AmVac. 'It is an excellent opportunity to leverage our investments and create significant potential for patients and investors - even more so, as both projects are expected to complete first clinical trials within the funding periods,' Melinda Karpati, CEO of AmVac comments.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more